> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AstraZeneca Wins Priority Voucher for Koselugo
- URL: https://www.fdaweb.com/astrazeneca-wins-priority-voucher-for-koselugo/
- Published: 2020-09-16T12:00:00.000Z
- Updated: 2026-09-14T16:28:58.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147660

*Federal Register* notice: FDA has issued a priority review voucher to AstraZeneca for an approved rare pediatric disease product — Koselugo (selumetinib), indicated for treating pediatric patients two years of age and older with neurofibromatosis Type 1 who have symptomatic, inoperable plexiform neurofibromas. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-09-16/pdf/2020-20387.pdf?ref=fdaweb.com).